博拓生物(688767)：战略参股“皓世天辉” 脑机接口侵入/非侵入全链条布局日趋完善

Core Insights - The investment agreement between Botao Bio's subsidiary Botai Zhito and Hangzhou Haoshi Tianhui marks a significant step in the brain-computer interface (BCI) industry, enhancing the commercial viability of the sector [1][2] Group 1: Investment and Strategic Development - Botai Zhito has completed a strategic investment in Haoshi Tianhui, becoming the sole investor in this financing round [1] - This investment complements Botao Bio's previous strategic stake in Qingshi Yongjun, establishing a dual technology path in both invasive and non-invasive BCI [2] Group 2: Company and Product Overview - Haoshi Tianhui is an innovative high-tech enterprise focused on AI in healthcare, with a strong founding team possessing overseas entrepreneurial experience and deep technical expertise [2] - The company's core AI and non-invasive BCI products aim to create a closed-loop service for various mental health issues, including depression and anxiety, through assessment, intervention, and feedback [2] Group 3: Financial Projections - Revenue forecasts for the company from 2025 to 2027 are projected at 496 million, 693 million, and 887 million yuan, reflecting a year-on-year change of -11.42%, +39.78%, and +28.11% respectively [3] - The net profit attributable to the parent company is expected to be 60 million, 158 million, and 215 million yuan for the same period, with year-on-year changes of -64.49%, +162.50%, and +35.95% respectively [3]